Nóra Hosszúfalusi

Nóra Hosszúfalusi

Auto-generated profile, based on publicly available information

Nóra Hosszúfalusi

Semmelweis University

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2003 in Diabetes Care
Verified
Journal Article
Open access
PDF file
NHNóra Hosszúfalusi
Nóra Hosszúfalusi
AVÁgnes Vatay
Ágnes Vatay
KRKatalin Rajczy
Katalin Rajczy
ZPZoltán Prohászka
Zoltán Prohászka
EPÉva Pozsonyi
Éva Pozsonyi
PPPál Pánczél
Pál Pánczél
OBJECTIVE—To compare the clinical parameters, C-peptide levels, pattern of islet cell-specific autoantibodies, and prevalence of predisposing genotypes in subjects with latent autoimmune diabetes in adults (LADA) and those with adult-onset type 1 diabetes with rapid progression.

1 October 2013 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
ABA. Barker
A. Barker
ALA. Lauria
A. Lauria
NSN. Schloot
N. Schloot
NHN. Hosszufalusi
N. Hosszufalusi
JLJohnny Ludvigsson
Johnny Ludvigsson
PPPaolo Pozzilli
Paolo Pozzilli

14 November 2006 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
NSNanette C. Schloot
Nanette C. Schloot
GMGuido Meierhoff
Guido Meierhoff
CLCsaba Lengyel
Csaba Lengyel
GVGyözö Vándorfi
Gyözö Vándorfi
JTJózsef Takács
József Takács
GJGyörgy Jermendy
György Jermendy


1 September 2002 in Clinica Chimica Acta
Verified
Journal Article
Closed access
IKIstván Karádi
István Karádi
ZMZsuzsa Mészáros
Zsuzsa Mészáros
ACAttila Csányi
Attila Csányi
TSTamás Szombathy
Tamás Szombathy
NHNóra Hosszúfalusi
Nóra Hosszúfalusi
KMKálmán Magyar
Kálmán Magyar

19 August 2009 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
GNGeza Nagy
Geza Nagy
RKReka Kovacs-Nagy
Reka Kovacs-Nagy
EKEva Kereszturi
Eva Kereszturi
ASAniko Somogyi
Aniko Somogyi
AVAnna Veres-Székely
Anna Veres-Székely
MSMaria Sasvari-Szekely
Maria Sasvari-Szekely
Background: Hypoxia inducible factor-1 alpha (HIF-1α) is a transcription factor that plays an important role in neo-vascularisation, embryonic pancreas beta-cell mass development, and beta cell protection. Recently a non synonymous single nucleotide polymorphism (g.C45035T SNP, rs11549465) of HIF-1α gene, resulting in the p.P582S amino acid change has been shown to be associated with type 2 diabetes (T2DM) in a Japanese population. Our aim was to replicate these findings on a Caucasian (Hungarian) population, as well as to study whether this genetic effect is restricted to T2DM or can be expanded to diabetes in general. Methods: A large Caucasian sample (N = 890) was recruited including 370 T2DM, 166 T1DM and 354 healthy subjects. Genotyping was validated by two independent methods: a restriction fragment analysis (RFLP) and a real time PCR using TaqMan probes. An overestimation of heterozygotes by RFLP was observed as a consequence of a nearby SNP (rs34005929). Therefore genotyping results of the justified TaqMan system were accepted. The measured genotype distribution corresponded to Hardy-Weinberg equilibrium (P = 0.740) Results: As the TT genotype was extremely rare in the population (0.6% in clinical sample and 2.5% in controls), the genotypes were grouped as T absent (CC) and T present (CT and TT). Genotype-wise analysis showed a significant increase of T present group in controls (24.0%) as compared to patients (16.8%, P = 0.008). This genetic effect was demonstrated in the separated samples of type 1 (15.1%, P = 0.020), and also in type 2 (17.6%, P = 0.032) diabetes. Allele-wise analysis gave identical results showing a higher frequency of the T allele in the control sample (13.3%) than in the clinical sample (8.7%, P = 0.002) with similar results in type 1 (7.8%, P = 0.010) and type 2 (9.1%, P = 0.011) diabetes. The odds ratio for diabetes (either type 1 or 2) was 1.56 in the presence of the C allele. Conclusion: We confirmed the protective effect of a rare genetic variant of HIF-1α gene against type 2 diabetes in a Caucasian sample. Moreover we demonstrated a genetic contribution of the same polymorphism in type 1 diabetes as well, supporting a possible overlap in pathomechanism for T2DM and a T1DM.